MSB 2.51% 97.0¢ mesoblast limited

ASX Hot too!, page-446

  1. 342 Posts.
    lightbulb Created with Sketch. 370
    Agree with you, @Phaedrus, that the company was juggling too many balls or dealing with too much uncertainty in December. I don’t like the level at which the CR was done, but people also don’t seem to realise or remember how much of a massive as well as crucial turnaround the company went through in the first quarter, in so many different ways. Could there have been less dilution? Perhaps, but I personally believe that the company might have been on its knees without the cap raise, in which case the “adaptation” of the FDA would have been completely futile. Instead, in a quick succession of moves, it got the ship righted.

    Hand on heart, as a top 500 shareholder I can say I have applauded the management team’s moves in the last few months.


    Last edited by irenekwshiu: 02/05/24
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.